Secure CheckoutPersonal information is secured with SSL technology.
Free ShippingFree global shipping
No minimum order.
Therapeutic Application of Nitric Oxide in Cancer and Inflammatory Disorders presents updated reviews on the chemistry, signaling, pre-clinical and clinical activities on the role of nitric oxide donors/inhibitors used alone and in combination with other therapeutic agents for the treatment of a variety of diseases. This book examines various studies related to the application of novel therapeutic NO (donors/inhibitors) compounds in the treatment of various cancers. These studies have been shown to exert significant therapeutic activities against various cancers and various inflammatory diseases such as rheumatoid arthritis, Crohn’s disease, allergies, and asthma, where no current effective therapies exist. Pathologies based on functional and structural vascular alterations are also taken into consideration.
Edited and written by internationally renowned experts in the field of novel therapeutics for cancer, this book is a valuable source for cancer researchers, medical scientists, clinicians, clinical pharmacologists, and graduate students.
- Provides readers with a clear overview of the recent findings and references as well as summaries, significant molecular pathways, and conclusions
- Discusses new ideas proposed and makes suggestions for further investigations that will advance the field
- Presents introductory and summary information on the contributions of the field, all the findings of the studies discussed, and projects future goals for research
Cancer researchers, medical scientists, clinicians, graduate students
I. Applications of Nitric Oxide in Cancer
1. Nitric Oxide-Releasing Engineered Nanoparticles: Tools for Overcoming Drug Resistance in Chemotherapy
2. Reversal of Multiple Cancer Oncogenic Pleiotropic Properties by NO-modulating Therapies
3. Antitumor Effect of a Metal Nonoate Through Angiogenesis Impairment
4. Therapeutic Implications of the Nitric Oxide Pathway in the Angiogenesis of Tumors and Inflammatory-Related Disorders
5. Nitric oxide and cancer: To inhibit or to induce iNOS – That is the Question?
6. Arginine Metabolism Regulates Nitric Oxide Production in Melanoma Tumor Microenvironment to Provide Survival Advantage to Tumor Cells
7. Cancer and Beyond: Discovery and Development of NO-releasing Therapeutics
8. Nitric Oxide Scavenging-Based Therapies for Targeting Colorectal Cancer
9. Therapeutic Aspects of Protein Denitrosylation
10. Nitric Oxide-Releasing Functional Nanomaterials for Anticancer Therapy
II. Applications of Nitric Oxide in Inflammatory-Related Disorders
11. The Role of Nitric Oxide on Vascular Dysfunction During Aging and Alzheimer’s Disease
12. Carbonic Anhydrase Inhibitor – NO Donor Hybrids and Their Pharmacologic Applications
13. Understanding the Roles of Nitric Oxide During Sepsis, an Inflammatory Disorder
14. Nanoporous Materials: New Generation of Nitric Oxide Donors
III. Abstracts (Presentations at Conference in Siena, October 4th-5th, 2018)
A. Serum Nitric Oxide Metabolites and The Incidence of Metabolic Syndrome and Its Phenotypes: A Population-Based Prospective Study
B. Nitric Oxide (NO): A Multifaceted Target for Reversal of Cancer Cell Pleiotropic Properties by NO-modulating Therapies
C. Pharmacology of Hepatoselective Nitric Oxide - Donors in NAFLD in Mice
D. New NO-Releasing Doxorubicins as Targeted Therapy Against Chemoresistance in Castration-resistant Prostate Cancer: In Vitro and In Vivo Evaluations
E. Anticancer Effect of a Novel H2S-Hybrid Molecule on Human Breast Adenocarcinoma (MFC-7) and Human Breast Epithelial (MCF-10A) Cell Lines
F. Heme Oxygenase-1 In Duchenne Muscular Dystrophy: Interaction with Nitric Oxide Synthase Pathway in Satellite Cells Differentiation
G. In Vitro Assessment of NitDox Toxicity Towards Vasculature
H. The Regulation of GSNOR Expression Discloses the Role of S-nitrosylation in Aging and Disease
I. Effects of Long-term Nitrite Supplementation on Gene Expressions of GLUT2, GLUT4 and Glucokinase in Male Obese Type 2 Diabetic Rats
J. Nitric Oxide Re-Instates Doxorubicin Cytotoxic and Pro-Immunogenic Effects in Refractory Breast Cancer
K. Anti-Cancer Activities of Erucin a H2S-donor Isothiocyanate from Eruca Sativa Mill.: Is H2S the Real Player?
L. Hydrogen Sulfide as a Signaling Molecule in The Cardiovascular System: Actions and Interactions with NO
M. Nitric Oxide in Cancer Resistance to Cisplatin: Tumor Associated Macrophages as Key Players.
N. Therapeutic Potential of Nitric Oxide Modulation in Ocular Diseases: A Focus on Novel NO-Releasing Molecules
O. Pro-Apoptotic Effects of S-Nitrosothiols O-Chloro and M-Chloro S-Nitroso-Aryl-Amides in Human Breast Cancer Cell Lines
P. Light Guided Production of Nitric Oxide and Singlet Oxygen for the Multi-Modal Treatment of Cancer
Q. Potential for Chemoprevention with Nitric Oxide- and Hydrogen Sulfide-Releasing Drugs
R. H2S Metabolism in Colon Cancer Cells Exposed to Hypoxia
- No. of pages:
- © Academic Press 2019
- 14th February 2019
- Academic Press
- Hardcover ISBN:
- eBook ISBN:
Dr. Morbidelli’s experience is within the pharmacology of angiogenesis and microcirculation by means of a plethora of in vitro and in vivo models. Since 1993 she contributed to demonstrate the role of nitric oxide pathway in the process of angiogenesis induced by growth factors and drugs. She published 130 papers and chapters in books on the molecular and cellular aspects of angiogenesis mainly in relation to tumor development and progression. From 2012 to 2015, she was a member of the COST Action BM1005 “European Network on Gaseoustransmitters” taking part to the annual meeting of the network and collaborating/interacting with members of the European Union. In the last years, as founder and partner of a spin-off devoted to the development of NO donors, she is contributing to characterize new NO donors in cardiovascular, cancer and inflammation related disorders.
Professor, Department of Life Sciences, University of Siena, Siena, Italy
Benjamin Bonavida, PhD, has been involved in the field of immunology and cancer biology for several decades and has published extensively in the fields of cancer resistance, chemotherapy, immunotherapy, and various molecular approaches to circumvent the resistance of the cancer cells using sensitizing agents. Accordingly, he was the first to publish a book on tumor sensitization in 2008. More recently, Dr. Bonavida is the Series Editor of 3 series published by Elsevier/Academic Press (“Cancer Sensitizing Agents for Chemotherapy,” “Breaking Cancer Resistance to Therapeutic Antibodies,” and “Breaking Tolerance to Anti-Cancer Immunotherapy”) and several books have been published and many are in development. He has published extensively in the field of NK biology and cytotoxicity in the past, and many of these publications were in collaboration with the co-editor Dr. Anahid Jewett.
Professor, Department of Microbiology, Immunology and Molecular Genetics, University of California, Los Angeles, USA
Elsevier.com visitor survey
We are always looking for ways to improve customer experience on Elsevier.com.
We would like to ask you for a moment of your time to fill in a short questionnaire, at the end of your visit.
If you decide to participate, a new browser tab will open so you can complete the survey after you have completed your visit to this website.
Thanks in advance for your time.